Showing 61 - 80 results of 224,941 for search '(( e fold decrease ) OR ( 10 ((((ng decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.45s Refine Results
  1. 61
  2. 62
  3. 63

    <i>Dmxl2</i> knockdown in INS-1E cells decreases glucose-induced insulin release. by Brooke Tata (633065)

    Published 2014
    “…(B) Seventy-two hours after the transfection of INS-1E cells with <i>Dmxl2-</i>siRNA, <i>Dmxl2</i> mRNA levels had decreased by 75% (error bars: SEM; from three independent experiments). …”
  4. 64
  5. 65
  6. 66
  7. 67

    Decreasing ShcA expression enhances TGF-β-induced Smad signaling. by Baby Periyanayaki Muthusamy (838234)

    Published 2015
    “…(D, E) Decreasing ShcA expression, upon transfection of ShcA siRNA (siShc-a for NMuMG cells, siShc-c for HaCaT cells) but not control siRNA, enhances Smad3-mediated transcription, quantified by luciferase expression from a 4xSBE-luciferase reporter, in NMuMG (D) and HaCaT (E) cells, in the absence of or in response to 0.8 ng/ml TGF-β, or treated with SB431542, for 6 h. …”
  8. 68
  9. 69
  10. 70
  11. 71
  12. 72
  13. 73

    Decreased miR-24 sensitizes cells to apoptotic stimuli, and increases pro-apoptotic protein expression. by Tan Nguyen (278146)

    Published 2013
    “…<b>A</b>) 32Dcl3 and knockdown cells were washed out of 10 ng/ml IL-3 containing media. …”
  14. 74

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…The overall median rank of VRK1 mRNA overexpression was 947 (out of 19,273 measured genes) (p = 3.64x10<sup>-28</sup>). Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  15. 75
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80